



PKI (14-22), Myristoylated

PRODUCT ANALYSIS SHEET

Catalog Number:	PHZ1202
Lot Number:	See product label
Quantity:	500 µg
Appearance:	Lyophilized solid
Sequence:	N-myristoyl-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-NH ₂
Molecular Weight:	1208.0
Purity:	>95%, as assessed by HPLC
Peptide Content:	85%
Form:	Trifluoroacetate salt. 500 µg net peptide/vial.
Summary:	PKI (14-22), myristoylated is a cAMP-dependent protein kinase inhibitor whose sequence is from the heat-stable skeletal muscle inhibitor protein of PKA and whose N-terminus is myristoylated to increase cell membrane permeability. The peptide binds to the catalytic subunit of PKA and displaces the regulatory subunit to inhibit its action.
Biological Activity:	K _i = 36 nM.
Solubility:	Soluble in H ₂ O.
Storage:	Store, as supplied, at -20°C, preferably desiccated. Upon solubilization, apportion into working aliquots and store at ≤ -20°C. Avoid repeated freeze/thaw cycles. Solutions are stable at ≤ -20°C for up to three months.
Expiration Date:	Expires one year from date of receipt when stored as instructed.
Related Products:	ERK1&2 [pTpY ^{185/187}] antibody, Cat. # 44-680G Tau [pS ²⁶²] antibody, Cat. # 44-750G Tau [pT ²¹²] antibody, Cat. # 44-740G Tau [pS ³⁵⁶] antibody, Cat. # 44-751G Tau [pS ²¹⁴] antibody, Cat. # 44-742G Tau [pS ⁴⁰⁹] antibody, Cat. # 44-760G
Caution:	Avoid contact with eyes, skin, and mucous membranes. Wear protective clothing when handling this product. Not for human use.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PHZ1202

(Rev 2.0) DCC-08-1232

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.



References:

- Glass, D.B., et al. (1989) Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. *J. Biol. Chem.* 264(15):8802-8810.
- Lohse, M.J., et al. (1990) Multiple pathways of rapid beta 2-adrenergic receptor desensitization. Delineation with specific inhibitors. *J. Biol. Chem.* 265(6):3202-3211.
- Walsh, D.A. and D.B. Glass (1991) Utilization of the inhibitor protein of adenosine cyclic monophosphate-dependent protein kinase, and peptides derived from it, as tools to study adenosine cyclic monophosphate-mediated cellular processes. *Methods Enzymol.* 201:304-316.
- Inglefield, J.R., et al. (2002) Identification of calcium-dependent and -independent signaling pathways involved in polychlorinated biphenyl-induced cyclic AMP-responsive element-binding protein phosphorylation in developing cortical neurons. *Neuroscience* 115(2):559-573.
- Liu, F., et al. (2001) Role of cAMP-dependent protein kinase A activity in endothelial cell cytoskeleton rearrangement. *Am. J. Physiol. Lung Cell Mol. Physiol.* 280(6):L1309-L1317.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PHZ1202

(Rev 2.0) DCC-08-1232

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

